Abstract: Objective : To evaluate the efficacy and safety in the combined chemotherapy of paclitaxel with cisplatin on anthracycine -resistant advanced breastcancer. Methods : From March 2000 to October 2002, 48 patients with anthracycine -resistant advanced breast cancer were treated by therapeutic alliance of paclitaxel with cisplatin. The mean number of cycles was 3 (range2-5). Results : The overall response rate (CR+PR) was 56.2% for CR6, PR21, SD12 and PD9, respectively. The mean time of paracme was 6.5 months (range 2 to 12 months). The main side effect included bone marrow depression, emesis and nausea, and pain of joint and muscle. Conclusion : The regimen of paclitaxel plus cisplatin is active in treatment of nathracycine -resistant advanced breast cancer, with an acceptable drug tolerance.